{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Octreotide+Depot&page=2", "query": { "intervention": "Octreotide Depot", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Octreotide+Depot&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T03:46:43.597Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04125836", "title": "A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acromegaly" ], "interventions": [ { "name": "CAM2029 (octreotide subcutaneous depot)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Camurus AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2019-10-10", "completion_date": "2025-04-24", "has_results": false, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-09-26T03:46:43.597Z", "location_count": 12, "location_summary": "Los Angeles, California • Palo Alto, California • Miami, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04125836" }, { "nct_id": "NCT00001860", "title": "Sandostatin LAR Depot vs. Surgery for Treating Acromegaly", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acromegaly", "Pituitary Neoplasm" ], "interventions": [ { "name": "Sandostatin LAR Depot versus transsphenoidal surgery", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 5, "start_date": "1999-08", "completion_date": "2002-07", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-09-26T03:46:43.597Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001860" }, { "nct_id": "NCT00182754", "title": "Octreotide in Treating Patients With Cancer-Related Malignant Ascites", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "octreotide acetate", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2005-10", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2017-04-11", "last_synced_at": "2026-09-26T03:46:43.597Z", "location_count": 122, "location_summary": "Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 68 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00182754" }, { "nct_id": "NCT00363051", "title": "Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Islet Cell Carcinoma", "Neuroendocrine Carcinoma", "Neuroendocrine Tumor", "Pancreatic Neoplasms" ], "interventions": [ { "name": "Everolimus 10 mg", "type": "DRUG" }, { "name": "Octreotide Depot", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2006-06", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2013-05-10", "last_synced_at": "2026-09-26T03:46:43.597Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00363051" }, { "nct_id": "NCT01137682", "title": "Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acromegaly" ], "interventions": [ { "name": "Pasireotide", "type": "DRUG" }, { "name": "octreotide LAR 30mg", "type": "DRUG" }, { "name": "lanreotide ATG 120mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 198, "start_date": "2010-07-19", "completion_date": "2017-02-28", "has_results": true, "last_update_posted_date": "2018-04-05", "last_synced_at": "2026-09-26T03:46:43.597Z", "location_count": 4, "location_summary": "Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas + 1 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01137682" }, { "nct_id": "NCT01789281", "title": "Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Sandostatin LAR Depot", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2013-05-14", "completion_date": "2020-08-28", "has_results": true, "last_update_posted_date": "2021-06-11", "last_synced_at": "2026-09-26T03:46:43.597Z", "location_count": 13, "location_summary": "Little Rock, Arkansas • Greenwood Village, Colorado • Stamford, Connecticut + 10 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Greenwood Village", "state": "Colorado" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01789281" }, { "nct_id": "NCT03972488", "title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastro-enteropancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Lutathera", "type": "DRUG" }, { "name": "30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)", "type": "DRUG" }, { "name": "2.5% Lys-Arg sterile amino acid solution", "type": "DRUG" }, { "name": "High dose 60 mg octreotide long-acting repeatable", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advanced Accelerator Applications", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2020-01-08", "completion_date": "2027-10-29", "has_results": true, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-09-26T03:46:43.597Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03972488" }, { "nct_id": "NCT00853047", "title": "Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoid Syndrome" ], "interventions": [ { "name": "Telotristat etiprate", "type": "DRUG" }, { "name": "Octreotide LAR Depot", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lexicon Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2009-03", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2018-12-26", "last_synced_at": "2026-09-26T03:46:43.597Z", "location_count": 9, "location_summary": "Little Rock, Arkansas • San Francisco, California • Indianapolis, Indiana + 6 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00853047" }, { "nct_id": "NCT04076462", "title": "A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acromegaly" ], "interventions": [ { "name": "CAM2029 (octreotide subcutaneous depot)", "type": "DRUG" }, { "name": "Matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Camurus AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2019-08-19", "completion_date": "2023-05-02", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-26T03:46:43.597Z", "location_count": 12, "location_summary": "Los Angeles, California • Palo Alto, California • Miami, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04076462" }, { "nct_id": "NCT05050942", "title": "A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastro-enteropancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "CAM2029", "type": "DRUG" }, { "name": "Octreotide LAR", "type": "DRUG" }, { "name": "Lanreotide ATG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Camurus AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 332, "start_date": "2021-10-22", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-26T03:46:43.597Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Santa Monica, California • Denver, Colorado + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05050942" } ] }